Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions

Tom Powles shared a post on X, about recent paper published in ESMO Open:

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.

Authors: Andrea Apolo, Joaquim Bellmunt, Lisa Cordes, Shilpa Gupta, Thomas Powles, Jonathan Rosenberg, Michiel van der Heijden.

”Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria.”

Source: Tom Powles/X

Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.